AzTrials
AzTrials

Brain Tumor AdultNCT04390906

A Study of Cognitive Changes in Patients Receiving Brain Radiation

An observational study of Brain Tumor Adult, run by University of Rochester at 1 site in United States.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Brain Tumor Adult
How many people
75 participants
Where
1 siteUnited States
Study dates
16 Oct 2018to 1 Jan 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Patients with low grade or benign brain tumors planned to receive partial brain radiation.

Who may be able to join

  • >18 years old patients with brain tumors including low grade gliomas, meningiomas, acoustic neuromas, pituitary adenomas, craniopharyngiomas, hemangiopericytomas, pineal tumors, and other benign or slow-growing brain tumors
  • Pathologic diagnosis will be required for gliomas, but not for other tumor types (though it will be recorded if available)
  • Within 3 months prior to registration, patients must have a post gadolinium contrast-enhanced three dimensional spoiled gradient (SPGR), magnetization-prepared rapid gradient echo (MP-RAGE), or turbo field echo (TFE) MRI scan and an axial T2/FLAIR sequence. To yield acceptable image quality with the smallest possible axial slice thickness, , the imaging protocol should include the standard brain tumor protocol sequences: long DTI, sagittal SPGR, and brainlab sequences, resting functional MRI or their equivalent.
  • Patients will need to be planned to receive fractionated radiation therapy or stereotactic radiation therapy, either fractionated or single fraction (enrollment must occur prior to radiation therapy so that baseline neurocognitive evaluation can be done)
  • Surgical excision and/or chemotherapy treatment prior to enrollment is allowed
  • Concurrent chemotherapy with radiation is allowed
  • Antiepileptic drugs use, seizures, steroids, anticholinergic medications will be recorded but patients will not be excluded
  • Hydrocephalus will be recorded, but patients will not be excluded

Who cannot join

  • Prior cranial radiation therapy
  • Other active malignancy
  • Contraindication to MRI imaging such as implanted metal devices or foreign bodies
  • Contraindication to gadolinium contrast administration during MR imaging such as allergy or insufficient renal function
  • Intractable seizures while on adequate anticonvulsant therapy-more than 1 seizure per month for the past 2 months
  • Life expectancy <6 months due to other severe comorbidity
Show all 10Show fewer
  • Due to limitations in our ability to test patients in languages other than English, patients will have to be English-speaking
  • Diagnosis of pre-existing dementia (clinically significant as defined by a neurologist or other provider), neurodegenerative, or neuro-inflammatory conditions as made by an appropriate health care professional such as a neurologist
  • Inability to participate in neuro-cognitive testing
  • Significant aphasia leading to difficulty participating in neuro-cognitive testing

Trial locations and contacts

1 site in 1 country.

United States1 site
  • James P. Wilmot Cancer Center at University of Rochester Medical Center

    Rochester, New York, 14642

Other trials in United States

About this study

Official title: A Prospective Pilot Study of Cognitive Changes in Patients Receiving Partial Brain Radiation: Development of a Radiation Dose-toxicity Model for Neuroanatomic Targets

Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. The study will prospectively enroll 75 patients with benign and low-grade brain tumors who will undergo partial brain RT, with either conventionally fractionated or hypofractionated schedules. Subjects will receive MRI scans at baseline, 6 months, and 12 months. Given the role of the limbic system in key cognitive functions affected by RT, researchers have a particular interest in characterizing MRI changes in the limbic system and thalamus in relation to memory and related processes.

Specific Aims:

Read more
  1. To examine objective neurocognitive changes over time. The investigators hypothesize that they will see RT-induced neurocognitive impairment in up to 50% of patients after cranial RT.
  2. To examine changes in brain tissue (via MRI) induced by off-target RT in patients with benign and low-grade brain tumors. The investigators specifically hypothesize that comapping of RT dose and MRI changes in the thalamus and limbic system (i.e., thalamic nuclei, hippocampus, fornix, hypothalamus/mammillary bodies, limbic lobe, cingulum) will be most distorted by off-target RT.
  3. To examine the relationship between MRI changes for key neuroanatomic structures identified in Aim 1 with objective neurocognitive testing. The investigators hypothesize that cognitive decline will be correlated with damage revealed by MRI to limbic and thalamic structures.

This research will help to define which neuroanatomic structures are most at risk from RT-induced damage and will help ultimately establish new dose constraint guidelines for important structures to improve cognitive outcomes.

Read the detailed description

Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. This suggests that off-target RT, even at low doses, may have a negative cognitive impact by affecting neuroanatomic targets proximal or distal to the tumor. While constraints to minimize brain necrosis, ototoxicity, and optic neuropathy are well-established, RT dose tolerances for cognitive changes in key domains (memory, attention, executive function, and processing speed) that occur in RT-treated patients are poorly characterized. There is accumulating evidence that consideration of neuroanatomic targets could better explain cranial RT-mediated cognitive change. Additionally, a recent cooperative group phase III trial has shown that conformal avoidance of the hippocampus with whole brain RT can reduce cognitive impairment. Unfortunately, 60% of patients still had cognitive impairment at 6 months even with hippocampal avoidance, implying that other structures and networks are involved in cognitive deficits from RT and efforts to identify those structures are warranted. A major obstacle in the field has been difficulty identifying sites of off-target tissue damage that could impact cognition after RT. Given the role of the limbic system in key cognitive functions affected by RT, the investigators have a particular interest in characterizing changes in limbic system and thalamus in relation to memory and related processes.

The investigators plan to examine RT effects on neuroanatomic structures in the limbic system and thalamus as well as candidate structures identified systematically using magnetic resonance imaging (MRI). The investigators propose to prospectively enroll 75 patients with benign and low-grade brain tumors who will undergo partial brain RT, either conventionally fractionated or hypofractionated.

Neurocognitive testing will be obtained at baseline, 3, 6, and 12 months after RT using a battery of tests to assess visual and verbal memory, attention, executive function, and processing speed. Brain MRI, including high resolution T1 images, diffusion tensor imaging (DTI), and resting functional MRI (fMRI) sequences, will be evaluated at baseline, 6, and 12 months after RT.

This pilot study will provide preliminary data to identify key areas impacted by RT that can be followed up in future research.

Aim 1: To examine objective neurocognitive changes over time. Based on prior data, the investigators hypothesize that they will see RT-induced neurocognitive impairment in up to 50% of patients after cranial RT. The investigators will evaluate neurocognitive testing changes in the HVLT-R delayed recall (verbal memory) as their primary endpoint. As a secondary endpoint, they will evaluate a composite global deficit z-score as well as changes in cognitive domains of visual memory, attention, executive function and processing speed.

Aim 2: To examine changes in brain tissue (via MRI) induced by off-target RT in patients with benign and low-grade brain tumors. The investigators hypothesize that a detailed brain tissue injury mapping of off-target RT doses from pre to post-RT and reconstructed structural and functional connectivity (DTI and fMRI) will provide data on the relationship between RT dose and MRI changes in specific structures. The investigators specifically hypothesize that co-mapping of RT dose and MRI changes in the thalamus and limbic system (i.e., thalamic nuclei, hippocampus, fornix, hypothalamus/mammillary bodies, limbic lobe, cingulum) will be most distorted by off-target RT.

Aim 3: To examine the relationship between MRI changes for key neuroanatomic structures with neurocognitive testing. The investigators hypothesize that RT will impact several neuronal networks sub-serving multiple cognitive domains and cognitive decline (Aim 2) will be correlated with damage revealed by MRI to limbic and thalamic structures (Aim 1). This approach will allow identification of brain structures most associated with domain-specific cognitive impairment.

There is critical need for well-designed longitudinal studies that examine the impact of RT on neuroanatomic structures. Many of the studies that evaluate cognition with RT do not take into account neuroanatomic dose distributions. Even within the literature that evaluates neuroanatomic targets, there has not been a systematic approach to evaluation of neuroanatomic targets by RT. This research will help to define which neuroanatomic structures are most at risk from RT-induced damage and will help ultimately establish new dose constraint guidelines for important structures to improve cognitive outcomes.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04390906
Study groupRoleWhat they receive
All participantsParticipants will receive standard of care partial brain radiation therapy at discretion of their radiation oncologist

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change on HVLT-R delayed recall

    Serial neurocognitive testing using raw scores from the HVLT-R delayed recall

    Measured: baseline to 6 months

Secondary outcomes (5)
  1. Correlation of change in fractional anisotropy (FA) on diffusion tensor imaging (DTI) in the thalamus and limbic system with RT dose

    Correlation of longitudinal change in FA for limbic system white matter regions of interest and RT dose

    Measured: baseline to 6 months

  2. Correlation of change in mean diffusivity (MD) on diffusion tensor imaging (DTI) in the thalamus and limbic system with RT dose

    Correlation of longitudinal change in MD for limbic system white matter regions of interest and RT dose

    Measured: baseline to 6 months

  3. Correlation of change on resting state functional MRI (rs-fMRI) and RT dose

    Correlation of longitudinal change in connectivity measures for limbic system/thalamus regions of interest on rs-fMRI and RT dose

    Measured: baseline to 6 months

  4. Correlation of change in region of interest volumes and RT Dose

    Correlation of longitudinal change in volume for gray matter limbic system structures/thalamus on T1 MRI and RT dose

    Measured: baseline to 6 months

  5. Change in global cognitive function

    Serial neurocognitive testing using scores from the HVLT-R, BVMT-R, CTMT, COWA, DMS, PAL, ERT, SWM. Results from these tests will be combined into a composite global cognition z-score [-3 to +3]

    Measured: baseline to 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 May 2020
  2. Study start16 Oct 2018
  3. Primary completion1 Jan 2027 (estimated)
  4. Study completion1 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
75 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04390906
Sponsor's protocol ID
RSRB00070001
Status last verified
May 2026
First submitted
10 Apr 2020
Last updated
18 May 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Hardy SJ, Finkelstein AJ, Tivarus M, Culakova E, Mohile N, Weber M, Lin E, Zhong J, Usuki K, Schifitto G, Milano M, Janelsins-Benton MC. Cognitive and neuroimaging outcomes in individuals with benign and low-grade brain tumours receiving radiotherapy: a protocol for a prospective cohort study. BMJ Open. 2023 Feb 15;13(2):e066458. doi: 10.1136/bmjopen-2022-066458.

    PubMed 36792323

Questions about this trial

What is this clinical trial studying?

An observational study of Brain Tumor Adult, run by University of Rochester at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 18 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change on HVLT-R delayed recall (time frame: baseline to 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04390906, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in